MMRF Launches Fund to Invest in Innovative Firms for Multiple Myeloma Research
The Multiple Myeloma Research Foundation (MMRF) has launched the Myeloma Investment Fund in an effort to attract promising biotech and technology companies to the…
Myeloma
Cellectis Plans Clinical Trial to Test Donor-derived CAR T-cell Therapy, Possible Multiple Myeloma Treatment
Cellectis announced plans to open a Phase 1 clinical trial to evaluate UCARTCS1 — its first allogeneic (donor-derived) CAR T-cell therapy for multiple myeloma patients —…
Trial to Evaluate Daratumumab/Revlimid as Maintenance for Some Multiple Myeloma Patients
Janssen Biotech is planning a new Phase 3 clinical trial to explore a combination of under-the-skin daratumumab plus Revlimid (lenalidomide) as a maintenance treatment for…
MolMed Receives Green Light for Phase 1/2 Trial to Test CAR T-cell Therapy in Myeloma, Leukemia Patients
The Italian Medicines Agency has approved a first-in-human clinical trial testing MolMed’s investigational CAR T-cell product, CD44v6, for the treatment of acute myeloid…
Janssen Seeks Approval of Darzalex Add-on for Newly Diagnosed Multiple Myeloma Patients in Japan
Janssen has submitted an application to Japanese authorities seeking the approval of Darzalex (daratumumab) — in combination with standard Revlimid (lenalidomide) and dexamethasone — for the treatment of newly diagnosed …
Investigational Ygalo Shows Promise for Relapsed or Refractory Multiple Myeloma, Interim Data Show
Ygalo (melflufen), a novel compound under investigation for relapsed and refractory multiple myeloma, was well-tolerated and…
GSK Compound Showing Durable Response Rates in Advanced Multiple Myeloma, New Phase 1 Trial Data Find
New data from a Phase 1 clinical trial show treatment with GlaxoSmithKline‘s investigational antibody-drug conjugate, GSK2857916, was linked to year free of disease progression in…
OncoTracker Acquires Global Rights to Diagnostic Test, Possible Combo Therapy for Multiple Myeloma
OncoTracker has acquired worldwide rights to a diagnostic test and possible triple combination therapy for patients with multiple myeloma in an agreement with the…
European Panel OKs Approval of Triple Combination Therapies for Multiple Myeloma Patients
The European Medicines Agency‘s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Celgene‘s Revlimid (lenalidomide) and…
FDA Delays Decision on Selinexor’s Approval for Heavily Treated Multiple Myeloma
The U.S. Food and Drug Administration is delaying its decision on a new drug application (NDA) seeking approval of selinexor in combination with dexamethasone…
Recent Posts
- Treatment before surgery slows PDAC disease progression: Study
- Scientists discover tissue differences in brain cancer in children
- Elahere approved in EU as treatment for ovarian cancer
- Survival better with Blenrep combo than Darzalex for R/R myeloma
- Aucatzyl, a cell therapy, approved in US for adults with advanced B-ALL